<DOC>
	<DOCNO>NCT01584492</DOCNO>
	<brief_summary>The purpose clinical study compare improvement breathe single administration CHF 1535 50/6 pMDI ( fix combination corticosteroid drug beclomethasone 50 µg + formoterol 6 µg/puff , 2 inhalation , total dose 100/12 µg ) give spacer versus free combination beclomethasone 50 µg/puff pMDI ( 2 inhalation , total dose 100 µg ) give spacer plus formoterol 6 µg/puff pMDI ( 2 inhalation , total dose 12 µg ) give spacer term FEV1 0 12 hour asthmatic child . Additionally study aim evaluate effect dos CHF 1535 pMDI compare placebo effect lung function parameter , assess safety tolerability CHF 1535 dosages child .</brief_summary>
	<brief_title>Bronchodilator Effect CHF1535 pMDI Versus Free Combination Beclometasone Plus Formoterol pMDI Asthmatic Children</brief_title>
	<detailed_description>FEV1 0 12 hour standardise time statistically analyse take account treatment , period subject pre-dose FEV1 .</detailed_description>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Bronchodilator Agents</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<criteria>Written inform consent obtain parents/legal representative and/or subject ( appropriate ) Prepuberal male female outpatient , age ≥ 5 &lt; 12 year ( Tanner stage I II ) Clinical diagnosis asthma accord Global Strategy Asthma Management Prevention ( GINA ) revise version 2009 least six month prior screen visit . Already treat inhale short act Beta2agonists require / inhaled beclomethasone dipropionate 400 µg equivalent . Forced Expiratory Volume first second ( FEV1 ) ≥ 60 % ≤ 95 % predict normal value screen visit . A documented positive response reversibility test screen visit , define Delta FEV1 ≥ 15 % baseline , 15 minute 400 μg salbutamol pressurise Meter Dose Inhaler ( ATS/ERS taskforce 2005 ) . A cooperative attitude ability use pMDI spacer ( Aerochamber Plus Volumatic ) . Endocrinological disease chronic disease . Known sensitivity component study medication . Any concomitant disease require additional treatment topic systemic glucocorticosteroids . Allergy one component medication use . Intolerance contraindication treatment Beta2agonists and/or inhale corticosteroid . Having receive investigational drug within 2 month current study . Inability comply study procedure study treatment intake . Occurrence acute asthma exacerbation respiratory tract infection 4 week precede screen visit . Significant seasonal variation asthma asthma occur episodic exposure allergen chemical sensitizer . History cystic fibrosis , bronchiectasis alpha1 antitrypsin deficiency . History near fatal asthma ( e.g . brittle asthma , hospitalisation asthma exacerbation Intensive Care Unit ) . Diagnosis restrictive lung disease . Significant medical history and/or treatment cardiac , renal , neurological , hepatic , endocrine disease , laboratory abnormality indicative significant underlying condition , may interfere patient 's safety , compliance , study evaluation , accord investigator 's opinion . QTc interval ( Fridericia 's formula ) high 450 msec screen visit</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>